全文获取类型
收费全文 | 139765篇 |
免费 | 10323篇 |
国内免费 | 4080篇 |
专业分类
耳鼻咽喉 | 1589篇 |
儿科学 | 2427篇 |
妇产科学 | 1821篇 |
基础医学 | 8257篇 |
口腔科学 | 7735篇 |
临床医学 | 15904篇 |
内科学 | 19319篇 |
皮肤病学 | 2399篇 |
神经病学 | 7852篇 |
特种医学 | 4488篇 |
外国民族医学 | 41篇 |
外科学 | 13873篇 |
综合类 | 20139篇 |
现状与发展 | 23篇 |
一般理论 | 2篇 |
预防医学 | 5504篇 |
眼科学 | 2191篇 |
药学 | 10950篇 |
82篇 | |
中国医学 | 11934篇 |
肿瘤学 | 17638篇 |
出版年
2024年 | 346篇 |
2023年 | 2476篇 |
2022年 | 4463篇 |
2021年 | 6067篇 |
2020年 | 5680篇 |
2019年 | 5108篇 |
2018年 | 4815篇 |
2017年 | 5306篇 |
2016年 | 5618篇 |
2015年 | 5403篇 |
2014年 | 9783篇 |
2013年 | 12132篇 |
2012年 | 8147篇 |
2011年 | 8717篇 |
2010年 | 7163篇 |
2009年 | 6559篇 |
2008年 | 6460篇 |
2007年 | 6949篇 |
2006年 | 6261篇 |
2005年 | 5532篇 |
2004年 | 4477篇 |
2003年 | 4080篇 |
2002年 | 3381篇 |
2001年 | 3012篇 |
2000年 | 2465篇 |
1999年 | 1984篇 |
1998年 | 1674篇 |
1997年 | 1393篇 |
1996年 | 1167篇 |
1995年 | 1033篇 |
1994年 | 854篇 |
1993年 | 698篇 |
1992年 | 612篇 |
1991年 | 550篇 |
1990年 | 474篇 |
1989年 | 409篇 |
1988年 | 404篇 |
1987年 | 334篇 |
1986年 | 299篇 |
1985年 | 361篇 |
1984年 | 297篇 |
1983年 | 210篇 |
1982年 | 207篇 |
1981年 | 204篇 |
1980年 | 173篇 |
1979年 | 136篇 |
1978年 | 80篇 |
1977年 | 53篇 |
1976年 | 56篇 |
1975年 | 36篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
81.
82.
83.
Donald B. Penzien PhD ; Frank Andrasik PhD ; Brian M. Freidenberg PhD ; Timothy T. Houle PhD ; Alvin E. Lake III PhD; Gay L. Lipchik PhD ; Kenneth A. Holroyd PhD ; Richard B. Lipton MD ; Douglas C. McCrory MD ; Justin M. Nash PhD ; Robert A. Nicholson PhD ; Scott W. Powers PhD ABPP ; Jeanetta C. Rains PhD ; David A. Wittrock PhD 《Headache》2005,45(S2):S110-S132
Guidelines for design of clinical trials evaluating behavioral headache treatments were developed to facilitate production of quality research evaluating behavioral therapies for management of primary headache disorders. These guidelines were produced by a Workgroup of headache researchers under auspices of the American Headache Society. The guidelines are complementary to and modeled after guidelines for pharmacological trials published by the International Headache Society, but they address methodologic considerations unique to behavioral and other nonpharmacological treatments. Explicit guidelines for evaluating behavioral headache therapies are needed as the optimal methodology for behavioral (and other nonpharmacologic) trials necessarily differs from the preferred methodology for drug trials. In addition, trials comparing and integrating drug and behavioral therapies present methodological challenges not addressed by guidelines for pharmacologic research. These guidelines address patient selection, trial design for behavioral treatments and for comparisons across multiple treatment modalities (eg, behavioral vs pharmacologic), evaluation of results, and research ethics. Although developed specifically for behavioral therapies, the guidelines may apply to the design of clinical trials evaluating many forms of nonpharmacologic therapies for headache. 相似文献
84.
Tae-Jin Song M.D. Ph.D. David P. Eisenberg M.D. Prasad S. Adusumilli M.D. Michael Hezel B.S. Yuman Fong M.D. 《Journal of gastrointestinal surgery》2006,10(4):532-542
The rising incidence of hepatocellular carcinoma (HCC) in western countries, along with the poor prognosis offered by present-day
treatment modalities, makes novel therapies for this disease necessary. Oncolytic herpes simplex viruses (HSV) are replication-competent
viruses that are highly effective in the treatment of a wide variety of experimental models of human malignancies. This study
seeks to investigate the effectiveness of oncolytic herpes viruses in the treatment of primary HCC cell lines. Sixteen commercially
available human HCC cell lines were studied. G207 is an attenuated, replication-competent, oncolytic HSV engineered to selectively
replicate within cancer cells. Cell lines were tested for viral sensitivity to G207 and their ability to support viral replication
using standard cytotoxicity and viral replication assays. Eleven of 16 cell lines were moderately to highly sensitive to G207
viral oncolysis. HCC cell lines additionally demonstrated the ability to support viral replication in vitro with as high as
800-fold amplification of the administered viral dose observed. G207 is cytotoxic to, and efficiently replicates within, HCC
cell lines in vitro. From these data, we suggest that oncolytic HSV therapy may have a role in the treatment of HCC, and in
vivo studies are warranted.
Presented in part at the 2005 American Hepato-Pancreato-Biliary Association Congress, Hollywood, Florida, April 14–17, 2005.
Supported by grants R01CA75461 and R01CA72632 from the National Institutes of Health, and by grant MBC-99366 from the American
Cancer Society (Yuman Fong). 相似文献
85.
同步放化疗治疗中晚期食管癌60例 总被引:1,自引:0,他引:1
目的 观察对中晚期食管癌患者同步放化疗,疗效及毒副作用.方法 中晚期食管癌120例,随机分放化疗组60例(简称放化组)和单纯放疗组60例(简称单放组).放疗采用常规分割,DT40 Gy后缩小照射野,避开脊髓斜野照射,加量DT20~30 Gy,6~7周完成.放化组放疗1、4周后应用顺铂(DDP)20 mg/d、亚叶酸钙(CF)0.1 g/d,CF静脉滴注1/2量时5-氟尿嘧啶(5-Fu)500 mg/d静脉滴注,连续5 d为1个周期,化疗当天进行放疗.结果 放化组与单放组1、2、3年生存率分别为67%、46%、34%和52%、38%、24%;放射性肺炎分别为14例和12例;外周血细胞下降分别为26例和17例;胃肠道反应分别为25例和9例;死亡分别为38例和48例.两组治疗效果比较差异有统计学意义(P<0.05).结论 放疗同步PLF方案化疗治疗中晚期食管癌生存率高,毒副作用及不良反应低. 相似文献
86.
本文对采用自行研制的中草药浓缩剂“肠梗”治疗的粘连性肠梗阻425例进行临床分析。根据不同的病理及临床特征将其分为三种类型,其中广泛粘连型是“肠梗”治疗的最佳适应症,粘连扭转型是其禁忌证。并对中转手术的指征、时间等问题进行了讨论。认为该方法具有简单易行、安全可靠、成功率高的特点,是一种易于推广的治疗粘连性肠梗阻的有效方法,具有较高的临床实际应用价值 相似文献
87.
R.J.W. de Keizer 《International ophthalmology》1997,21(6):335-341
In a prospective study the results of a pterygium excision in 54 patients (57 eyes) who underwent a superficial free conjunctival
autograft (FCG) were compared to those of patients who were treated with postoperative90Sr-irradiation. In 51 cases the minimum
follow-up was six months, the maximum follow-up seven years. We divided the study up into a randomized part and an open part.
In the randomized part, surgery of a primary pterygium was performed in 25 eyes, of which 16 were treated with a FCG and compared
with 9 eyes with primary pterygium surgery and postoperative90Sr beta-irradiation. In the same period 16eyes were treated
because of a recurrent pterygium: 8 with FCG and 8 with90Sr-irradiation. In the open part of the study16 eyes with primary
pterygium were successively treated with FCG alone.
The results showed in the randomized, as well as in the open study on primary surgery with a minimum follow-up of six month,
one recurrence in each of the FCG-groups (2 out of 31 eyes =6.4%), and no recurrences in the 90Sr-group(0%). In the randomized
group of patients treated for a recurrent pterygium one recurrence developed in the FCG group (1 out of 8 eyes =12.5%) and
one in the 90Sr-group (1 out of 7 =14.6%). Analysis of other clinical parameters showed that postoperative treatment with
corticosteroids, nonsteroidal anti-inflammatory drugs, and artificial tears was necessary for a longer period in the FCG group
than in the90Sr-group.
This revised version was published online in August 2006 with corrections to the Cover Date. 相似文献
88.
89.
Fumio Nakajima Tomohiko Asano Masamichi Hayakawa Hiroshi Nakamura 《International journal of urology》1996,3(1):s19-s21
We evaluated nitric oxide induction in antitumor therapy consisting of anti–CD3 monoclonal antibody (anti–CD3) and interleukin–2 (IL–2), then determined the effect of nitric oxide reduction with L–NG –monomethyl arginine (LNMA) on the therapeutic methods. Female C57BL/6 mice, MCA102 (a non immunogenic, NK–resistant murine fibrosarcoma cell line), and 145–2C11 (hamster anti–murine–CD3 mAb) were utilized in an experimental hepatic metastasis model developed by injecting a tumor cell suspension into the spleen of mice. A marked increase in serum NO2 – + NO1 was observed at 19 hours after anti–CD3 (10 μ, IV) and additional IL–2 administrations (40times101 U, twice, If) induced a further increase. The NO2 , + NO3- elevation in spot urine in the combination therapy was not suppressed with LNMA at a dose of 100 μg/h but was significantly lowered at 300 μg/h. The efficacy of the anti–CD3 + IL–2 therapy was not diminished by LNMA administration either at 100 μg/h or at 300 μg/h. 相似文献
90.
Toshifumi Gabata Osamu Matsui Masumi Kadoya Samon Miyata Mitsuo Fujimura Tsutomu Takashima 《Cardiovascular and interventional radiology》1995,18(5):327-329
Gross hemorrhage is the most serious complication of anticoagulant therapy. We report the discovery and treatment of a large pseudoaneurysm of the superior gluteal artery in one patient who had been receiving oral anticoagulant therapy. We diagnosed the pseudoaneurysm by contrast-enhanced computed tomography, and embolized the artery with stainless steel coils. The exact cause of the pseudoaneurysm remains unclear, however, minor trauma appears most likely. 相似文献